I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience Multiple Sclerosis

Multiple sclerosis

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Apr 8 / Roche and Genentech
Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit-Risk Profile From the OCARINA II Study and Patient Preferences
Updated efficacy and safety data, and new patient-reported preference data are presented from the OCARINA II study.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 8 / Roche and Genentech
Fenebrutinib maintains low disease activity in relapsing multiple sclerosis: results from the FENopta trial open-label extension
This analysis assessed the efficacy, safety and exploratory biomarkers, such as immunoglobulins and B cells, after fenebrutinib treatment in people with RMS enrolled int he FENopta open-label extension through Week 48.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Placental and Breastmilk Transfer of Ocrelizumab from Women with Multiple Sclerosis to Infants and the Potential Impact on B-Cell Levels: Primary Analysis of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO
MINORE is a prospective Phase IV, open-label study measuring placental transfer of ocrelizumab and potential impact on newborn B-cell levels, with detailed maternal and infant clinical outcomes, humoral immunity, safety and serum biomarkers. SOPRANINO is the first prospective study measuring pharmacodynamic and pharmacokinetic parameters of ocrelizumab in breastmilk and potential effects on infant humoral response to vaccines, safety, growth and development.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 7 / Roche and Genentech
Reduced cerebrospinal fluid biomarkers (neurofilament light chain, B cells, T cells) and improved clinical/imaging assessments of disease activity are sustained after 5 years of ocrelizumab treatment: long-term extension results from OBOE
The long-term extension of this longitudinal study of ocrelizumab treatment in people with relapsing multiple sclerosis evaluated cerebrospinal fluid levels of neurofilament light chain, CD19+ B cells and CD3+ T cells up to 240 weeks.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Apr 6 / Roche and Genentech
Imaging and Fluid Biomarkers of Disability Progression During Two Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Multiple Sclerosis (MS) in CHIMES
CHIMES is a prospective, open-label, single-arm phase IV study of the efficacy and safety of ocrelizumab in Black/African American and Hispanic/Latino individuals with relapsing MS. This analysis assessed imaging and blood biomarkers of disease activity over 96 weeks of treatment.
Neuroscience Multiple Sclerosis AAN-2025

Sign up or login to unlock the full suite of MEDICALLY features
Feb 28 / Roche and Genentech
Real-world effectiveness of first-line ocrelizumab treatment in relapsing multiple sclerosis: insights from MSBase OCR-R sub-study
Real-world evidence on the effectiveness of ocrelizumab (OCR) in treatment-naïve patients, with relapsing multiple sclerosis (MS) remains limited. Here we present data from the ongoing 5-year MSBase OCR-R sub-study, in eight countries, measuring treatment persistence, disease activity, disability progression and improvement in patients with relapsing MS treated with ocrelizumab.
Neuroscience Multiple Sclerosis ACTRIMS-FORUM-2025
Treatment management Research advancements
  • Multiple Sclerosis
1 results

Sign up or login to unlock the full suite of MEDICALLY features
Oct 27 / Roche
The Mechanics of MS: an analogy to aid understanding of MS disease progression
This booklet for healthcare professionals provides additional context to the MS disease progression analogy, an analogy that was co-developed by representatives of the patient community and Roche. The brochure explains how and why the analogy was created and how it can be used as a tool to improve understanding of disease progression during conversations with patients.
Neuroscience Multiple Sclerosis ECTRIMS-2022
Upcoming congresses
Access to Roche and Genentech's latest medical information

Sign up or login to unlock the full suite of MEDICALLY features
May 13 - May 16, 2025 / Montreal, Canada / Virtual (Hybrid)
ISPOR 2025
Oncology Neuroscience Infectious Disease Ophthalmology Multiple Sclerosis Spinal Muscular Atrophy
Subject:
International Society for Pharmacoeconomics and Outcomes Research - 30th International Meeting
Venue:
Medical Booth Number:
Learn More
Bookmark this
Share page
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.